Please check your internet connection and try again.
# Methylcobalamin
## Overview
Methylcobalamin is a neurologically active form of Vitamin B12 (cobalamin). Unlike cyanocobalamin, it does not require metabolic conversion to be utilized by the central nervous system. It acts as a cofactor for methionine synthase, essential for DNA and protein synthesis and nerve tissue repair.
## Primary Indications
* Peripheral neuropathy (diabetic or toxic).
* Megaloblastic anemia due to Vitamin B12 deficiency.
* Hyperhomocysteinemia.
* Adjunctive therapy for subacute combined degeneration of the spinal cord.
## Adult Dosing
* **Peripheral Neuropathy:** 500 mcg orally 3 times daily (1,500 mcg/day total). Depending on severity, 500 mcg intramuscularly (IM) or intravenously (IV) 3 times weekly may be used.
* **Vitamin B12 Deficiency:** Dosing varies significantly by clinical severity and local protocol. Oral supplementation typically ranges from 1,000 mcg to 2,000 mcg daily. Severe deficiency often requires replenishment via IM injection (e.g., 1,000 mcg daily for 1–2 weeks, then monthly maintenance).
## Pediatric Dosing
* **General Deficiency:** No standard pediatric dosing for methylcobalamin exists; it is usually managed with cyanocobalamin. If used, dosages are extrapolated based on serum levels, ranging from 5 mcg/kg to 30 mcg/kg IM weekly, not to exceed adult doses.
* **Note:** Always verify specific local pediatric protocols or consult a pediatric specialist before initiating.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal dosage adjustments are established; however, since B12 is excreted renally, use caution in renal failure. Monitor for accumulation in patients with severe renal impairment.
## Contraindications
* Hypersensitivity to cobalt or any component of the formulation.
* Leber's hereditary optic neuropathy (administration may cause severe and rapid optic atrophy).
## Adverse Effects
* **Common:** Injection site reactions (pain, redness), rash, itching (urticaria), and gastrointestinal upset (nausea, diarrhea).
* **Rare:** Anaphylaxis, hypokalemia (during initial high-dose treatment for megaloblastic anemia due to increased erythrocyte production).
## Key Drug Interactions
* **Chloramphenicol:** May decrease the hematopoietic response to methylcobalamin.
* **Proton Pump Inhibitors (PPIs) and H2 Antagonists:** May decrease the oral absorption of cobalamins.
* **Colchicine/Neomycin:** May reduce oral absorption of B12.
* **Metformin:** Long-term use can lead to decreased B12 absorption; monitor levels regularly.
## Monitoring
* **Baseline:** Complete Blood Count (CBC), serum B12 levels, and folate levels.
* **Ongoing:** Hemoglobin/Hematocrit levels for anemia resolution, peripheral neuropathy symptoms, and serum potassium (during initial phase of severe deficiency treatment).
## Clinical Pearls
* **Efficacy:** Methylcobalamin is preferred over cyanocobalamin in patients with renal failure, as they may have difficulty converting cyanocobalamin to its active form.
* **Route of Administration:** Oral absorption is limited by Intrinsic Factor (IF). In cases of pernicious anemia or malabsorption syndromes (e.g., Crohn's, post-gastrectomy), IM injection is the mandatory route to bypass the GI tract.
* **Storage:** Protect from light; methylcobalamin is photolabile and can degrade when exposed to fluorescent or sunlight.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines vary by region and institution. Always verify specific dosing, safety, and contraindications against current prescribing information, institutional formulary, or local department protocols before prescribing or administering medication.
